Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 59.4% in May

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 19,000 shares, a decrease of 59.4% from the April 30th total of 46,815 shares. Based on an average trading volume of 85,097 shares, the short-interest ratio is currently 0.2 days. Currently, 0.7% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Cardio Diagnostics to a “hold” rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Cardio Diagnostics

A number of hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC bought a new stake in Cardio Diagnostics during the 1st quarter worth approximately $30,000. Citadel Advisors LLC purchased a new position in Cardio Diagnostics in the 3rd quarter worth approximately $79,000. Finally, DRW Securities LLC raised its position in shares of Cardio Diagnostics by 122.8% during the 4th quarter. DRW Securities LLC now owns 40,463 shares of the company’s stock valued at $110,000 after buying an additional 22,298 shares in the last quarter. 8.06% of the stock is currently owned by institutional investors.

Cardio Diagnostics Stock Up 4.8%

Cardio Diagnostics stock traded up $0.09 during mid-day trading on Friday, hitting $1.89. 60,187 shares of the stock were exchanged, compared to its average volume of 76,448. The firm’s fifty day simple moving average is $1.86 and its two-hundred day simple moving average is $2.52. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $7.91. The stock has a market capitalization of $5.59 million, a price-to-earnings ratio of -0.56 and a beta of 2.30.

Cardio Diagnostics (NASDAQ:CDIO) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.63) earnings per share (EPS) for the quarter. Cardio Diagnostics had a negative net margin of 36,950.00% and a negative return on equity of 78.82%.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.